Alpine Immune Sciences‘ ALPN-101, a treatment for inflammatory and autoimmune diseases that works by inhibiting two key pathways — ICOS and CD38 — is better at reducing immune cell activity than a combination of treatments targeting these molecules individually, suggests a study in cells and animal models of Sjögren’s…
News
Sjögren’s syndrome can be classified into four distinct groups based on symptoms, and these groupings may be suggestive of differences in underlying biology and even response to treatment, a new study suggests. The study, “Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international…
FemmePharma has been given a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Satisfaite, a delivery system for intravaginal lubricants that relieve the vaginal dryness associated with menopause, a symptom that affects women with Sjögren’s syndrome more than others. The clearance indicates that Satisfaite…
Pri-Med and the Sjogren’s Syndrome Foundation (SSF) recently partnered to present a continuing medical education session in Boston on the systemic autoimmune disease. Held Dec. 4 on the opening of the four-day Pri-Med East conference at the Boston Convention and Exhibition Center, the session was titled…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
Orencia (abatacept), an immunotherapy used in rheumatic diseases, failed to reduce disease activity in patients with early active primary Sjögren’s syndrome after 24 weeks of treatment, results from the ASAPIII Phase 3 trial show. However, more patients reported an easing of disease symptoms while taking Orencia, compared…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Non-invasive Test May Help Diagnose Peripheral Nerve Damage in Sjögren’s Patients, Study Suggests
A non-invasive test that measures nerve conduction through surface electrodes may help diagnose polyneuropathy — damage to multiple nerves outside the brain and spinal cord — in patients with Sjögren’s syndrome, a study suggests. The study, “Polyneuropathy and the sural/radial sensory…
Recurrent Aseptic Meningitis Can Be First Symptom of Sjögren’s Syndrome, Case Report Suggests
Doctors should suspect primary Sjögren’s syndrome when examining patients, especially young women, with recurrent aseptic meningitis — a form of inflammation of the meninges, a membrane protecting the brain and spinal cord, that is not caused by bacteria, a case report suggests. The study, “Recurrent aseptic meningitis:…
Interstitial lung disease (ILD), or lung tissue scarring, commonly occurs in people with primary Sjögren’s syndrome in China and significantly burdens their quality of life, in particular their physical capacity, a Chinese study reports. Strengthening early interventions and treatment is of great importance in preventing ILD and improving…
Recent Posts
- Childhood-onset Sjögren’s can cause lasting damage to organs: Study
- Salivary duct treatment eases dry mouth in Sjögren’s disease: Study
- 4 genes linked to inflammatory cell death very active in Sjögren’s
- AI can see what doctors miss to accurately diagnose Sjögren’s
- Worse fatigue tied to more pain in people with Sjögren’s, study finds
- Dazodalibep therapy now in Phase 3 testing for Sjögren’s disease
- Sjögren’s treatment ianalumab shows rapid disease relief in trials
- Sjögren’s patients on nipocalimab report less pain, dryness in trial
- Ouro starts Phase 1b trial of OM336 for Sjögren’s disease treatment
- Telitacicept eases Sjögren’s disease activity in Phase 3 trial